Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group

Cancer

Volumn 107, Issue 5, 2006, Pages 1014-1022

  Nickenig, Christina ^a   Dreyling, Martin ^a   Hoster, Eva ^a   Pfreundschuh, Michael ^b   Trumper, Lorenz ^c   Reiser, Marcel ^d   Wandt, Hannes ^e   Lengfelder, Eva ^f   Unterhalt, Michael ^a   Hiddemann, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e Municipal Hospital Nurnberg Nord   (Germany)

^f UNIVERSITY OF MANNHEIM   (Germany)

Author keywords

Chemotherapy; First line therapy; Indolent lymphoma; Randomized trial

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; MELPHALAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; GERMANY; GRANULOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR RECURRENCE;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISOLONE; PREDNISONE; SURVIVAL RATE; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33748294356     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22093     Document Type: Article

References (28)

1. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667-2674.
2. Sebban C, Belanger C, Brousse N, et al. Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 trial (G.E.L.A. Study Group). Blood. 2003;102:354. Abstract.
3. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105:3817-3823.
4. Czuczman MS. Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol. 2002;29(2Suppl 6):11-17.
5. Hainsworth ID, Litchy S, Morrissey LH, et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1500-1506.
6. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005;23:694-704.
7. Jaeger G, Neumeister P Brezinschek R, et al. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a Phase II study. Eur J Haematol. 2002;69:21-26.
8. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064-3071.
9. Hiddemann W, Kneba M, Dreyling M, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone-results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2005;106:3725-3732.
10. Herold M, Dolken G, Fiedler F, et al. Randomized Phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol. 2003;82:77-79.
11. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
12. Salles GA, Foussard C, Mounier N, et al. Rituximab added to IFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood. 2004;104:160. Abstract.
13. Landys KE. Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma. Invest New Drugs, 1988;6:105-113.
14. Unterhalt M, Herrmann R, Tiemann M, et al. Prednimustine, mitoxantrone (PmM) versus cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia. 1996;10:836-843.
15. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
16. Hiddemann W, Unterhalt M, Koch P, Nahler M, van de Loo J. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical Phase II study. Semin Oncol. 1990;17(6Suppl 10):20-23.
17. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst. 1993;85:1138-1148.
18. Whitehead J. A unified theory for sequential clinical trials. Stat Med. 1999;18(17-18):2271-2286.
19. Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. BMJ. 1978;1:533-537.
20. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol. 1998;16:2332-2338.
21. Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993;11:644-651.
22. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2003;21:5-15.
23. Cox JD. Cure and follicular lymphoma. Int J Radiat Oncol Biol Phys. 1997;38:1-2.
24. Rosenberg SA. Karnofsky Memorial Lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities. J Clin Oncol. 1985;3:299-310.
25. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447-8452.
26. Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin Oncol. 2000;27(6Suppl 12):30-36.
27. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87:33-43.
28. Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol. 2004;22:4926-4933.